2-(2-chloro-3-pyridinyl)-1,3-benzothiazole, also known as **CPBT**, is a small molecule that has shown promising activity in various research areas, particularly in **neuroscience** and **drug discovery**.
Here's a breakdown:
**Structure and Properties:**
* **Structure:** CPBT is a heterocyclic compound consisting of a benzothiazole ring fused to a pyridine ring with a chlorine atom at the 2-position of the pyridine ring.
* **Properties:** It's a white to off-white solid with a molecular weight of 246.71 g/mol.
**Research Significance:**
**1. Antidepressant Activity:** CPBT has been found to exhibit antidepressant-like effects in preclinical studies. It acts as a **potent and selective inhibitor of monoamine oxidase A (MAO-A)**, an enzyme that breaks down neurotransmitters like serotonin, norepinephrine, and dopamine. By inhibiting MAO-A, CPBT increases the levels of these neurotransmitters in the brain, which is believed to contribute to its antidepressant effects.
**2. Anti-inflammatory Activity:** Research suggests that CPBT possesses anti-inflammatory properties, potentially by modulating the activity of inflammatory mediators like cytokines. This activity has been explored in models of inflammation, including inflammatory bowel disease and arthritis.
**3. Anticancer Activity:** Studies have indicated that CPBT may have anticancer potential, particularly against certain types of cancer cells. Its mechanisms of action in cancer research are being investigated, but they may involve inhibiting cell proliferation, inducing apoptosis (programmed cell death), and interfering with signaling pathways associated with cancer development.
**4. Neuroprotective Effects:** Some research suggests that CPBT may protect neurons from damage, potentially by reducing oxidative stress and inflammation. This has implications for conditions like Alzheimer's disease and Parkinson's disease.
**5. Other Potential Applications:**
* **Antimicrobial activity:** CPBT has shown some antimicrobial effects against bacteria and fungi.
* **Anti-viral activity:** Research is ongoing to explore its potential against certain viruses.
**Current Research:**
CPBT is actively being investigated in preclinical studies to understand its mechanisms of action and therapeutic potential. Researchers are aiming to develop improved formulations and explore its safety and efficacy in animal models and, potentially, in clinical trials for specific conditions.
**Important Considerations:**
* **Safety and Toxicity:** As with any new drug candidate, the safety and potential toxicity of CPBT need to be thoroughly evaluated through preclinical and clinical studies.
* **Further Research:** While promising, CPBT's therapeutic potential is still under investigation. More research is needed to fully understand its mechanisms of action, optimize its properties, and assess its safety and efficacy for various applications.
**Conclusion:**
2-(2-chloro-3-pyridinyl)-1,3-benzothiazole (CPBT) is a promising small molecule with multiple research interests due to its potential in various therapeutic areas like antidepressant, anti-inflammatory, anticancer, and neuroprotective applications. While still in preclinical stages, it offers a potential new avenue for developing novel treatments for a range of diseases.
ID Source | ID |
---|---|
PubMed CID | 2764495 |
CHEMBL ID | 1405738 |
CHEBI ID | 122175 |
SCHEMBL ID | 13116807 |
Synonym |
---|
HMS2650G13 |
MLS000763697 |
2-(2-chloro-3-pyridinyl)-1,3-benzothiazole |
smr000334043 |
CHEBI:122175 |
AKOS005071332 |
2-(2-chloropyridin-3-yl)-1,3-benzothiazole |
9J-320S |
339112-40-2 |
SCHEMBL13116807 |
CHEMBL1405738 |
Q27210822 |
mfcd00243533 |
2-(2-chloropyridin-3-yl)benzo[d]thiazole |
Class | Description |
---|---|
benzothiazoles | |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Luciferase | Photinus pyralis (common eastern firefly) | Potency | 15.1014 | 0.0072 | 15.7588 | 89.3584 | AID588342 |
BRCA1 | Homo sapiens (human) | Potency | 17.7828 | 0.8913 | 7.7225 | 25.1189 | AID624202 |
ATAD5 protein, partial | Homo sapiens (human) | Potency | 16.4619 | 0.0041 | 10.8903 | 31.5287 | AID504466; AID504467 |
regulator of G-protein signaling 4 | Homo sapiens (human) | Potency | 50.1187 | 0.5318 | 15.4358 | 37.6858 | AID504845 |
euchromatic histone-lysine N-methyltransferase 2 | Homo sapiens (human) | Potency | 17.7828 | 0.0355 | 20.9770 | 89.1251 | AID504332 |
nuclear factor erythroid 2-related factor 2 isoform 2 | Homo sapiens (human) | Potency | 18.3564 | 0.0041 | 9.9848 | 25.9290 | AID504444 |
serine/threonine-protein kinase PLK1 | Homo sapiens (human) | Potency | 21.1923 | 0.1683 | 16.4040 | 67.0158 | AID720504 |
DNA polymerase iota isoform a (long) | Homo sapiens (human) | Potency | 89.1251 | 0.0501 | 27.0736 | 89.1251 | AID588590 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 3 (60.00) | 24.3611 |
2020's | 1 (20.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.56) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |